Share

    


Home / Search Results

Search Results

You searched for:

As immune checkpoint inhibitors have become the standard of care for eligible patients with NSCLC, frequent monitoring of irAEs as well as provider and patient education on the signs and symptoms of pneumonitis can ensure improved clinical outcomes for patients.
ACCC held a LinkedIn live event on March 13, 2023, with subject matter experts, who shared strategies for tackling lung cancer disparities in the Appalachian Region and beyond.
Care optimization is everything in today’s rapidly changing healthcare landscape. Learn how ACCC's nationwide quality improvement (QI) initiative helped Southern Ohio Medical Center Cancer Center develop and implement plans to support the optimization of care for patients diagnosed with Stages III and IV non-small cell lung cancer (NSCLC).
Communities around the globe recognize August 1 as World Lung Cancer Day—a day to commemorate, educate, and support individuals and families impacted by lung cancer. Read highlights on a few ACCC initiatives that are helping cancer care teams better support their patients with this disease.
The COVID-19 pandemic has had a negative impact in the rate of cancer screening across various states in the United States. Louisiana, Delaware, Kentucky and Northern Michigan serve as vehicles for an analysis of the disparity in cancer screening rates, before and after the pandemic.
A mix-method approach to understand clinician use of biomarker testing for patients with non-small cell lung cancer.
In launching its new campaign, "Transforming Complex To Clear," ACCC brought together expert panelists to discuss effective practices and offer tips to address current barriers to biomarker testing in the community setting.
An expert ACCC Steering Committee shares 32 informed treatment and care delivery recommendations for the ideal care of patients with non-small cell lung cancer.
This ACCC education program shares key highlights from a national survey of thoracic surgeons, radiation oncologists, and medical oncologists on the barriers that exist in the ideal management of patients with NSCLC.